Baxter International Inc.

Valuation Analysis

About the Company

Baxter International Inc. en bref

Baxter International Inc. (BAX) is currently trading at 17,35 € with a market capitalization of 9,0 Md €. The 52-week range spans from 13,71 € to 27,69 €; the current price is 37.3% below the yearly high. Year-over-year revenue growth stands at +2.9%.

💰 Dividende

Baxter International Inc. pays an annual dividend of 0,17 € per share, representing a yield of 1.01%. The payout ratio stands at 307.69%. The elevated payout ratio reflects a mature dividend policy.

📊 Avis des analystes

12 analystes évaluent Baxter International Inc. (BAX) au consensus : Conserver. L'objectif de cours moyen est de 18,78 €, soit un potentiel de +8.25% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 14,82 € à 34,87 €.

Baxter International Inc. : la thèse d'investissement en détail

Baxter International Inc. (BAX) operates in the Healthcare — specifically Medical Instruments & Supplies — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario baissier

Revenue growth has slowed to just 2.9%, which is below nominal GDP — the business is no longer outgrowing the broader economy. Net margins remain negative, meaning every euro of revenue is still producing losses — the path to profitability is the central question for shareholders. Short interest sits at 12.96% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong.

Valorisation en contexte

At a PEG of 36.68, investors are paying more than three times the growth rate for each unit of earnings — that pricing assumes growth not only continues but accelerates from here. The EV/EBITDA multiple of 9.54x is below the historical equity-market average — strategic acquirers would find the cash-flow profile attractive at this level.

Thèse d'investissement : forces et faiblesses

Aperçu technique

The price is in a transition zone relative to the moving averages — no clear signal.

Profil de risque

The data points to relatively defensive market behavior, elevated short interest (12.96%), higher leverage relative to equity.

Trading Data

💵 Dividend Info

Related Stocks in the Same Sector

Where can I buy Baxter International Inc.?

Compare top-rated brokers — low fees, trusted providers, fully regulated.